Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

September 23, 2024

Study Completion Date

December 31, 2029

Conditions
Cerebral Small Vessel DiseasesStroke, Ischemic
Interventions
DRUG

Tadalafil 20 MG

Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.

DRUG

Placebo

Daily dose of oral over-encapsulated placebo tablets for three months.

Trial Locations (2)

2650

Danish Research Centre for Magnetic Resonance, Hvidovre

2730

Department of Neurology, Herlev Gentofte Hospital, Herlev

All Listed Sponsors
collaborator

Danish Research Centre for Magnetic Resonance

OTHER

collaborator

Bispebjerg Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

The Novo Nordic Foundation

OTHER

collaborator

Nordsjaellands Hospital

OTHER

lead

Christina Kruuse

OTHER